These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 24836726)

  • 1. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension in Patients with Heart Failure with Reduced Ejection Fraction.
    Volpe M; Santolamazza C; Tocci G
    Curr Cardiol Rep; 2016 Dec; 18(12):127. PubMed ID: 27796865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
    Bayes-Genis A; Morant-Talamante N; Lupón J
    Curr Heart Fail Rep; 2016 Aug; 13(4):151-7. PubMed ID: 27260315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders.
    Tabrizchi R
    Drugs; 2003; 63(20):2185-202. PubMed ID: 14498755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
    Volpe M; Tocci G; Battistoni A; Rubattu S
    High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):241-6. PubMed ID: 26100410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.
    Dobrek Ł; Thor P
    Acta Pol Pharm; 2011; 68(3):307-16. PubMed ID: 21648184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure.
    Fu S; Chang Z; Luo L; Deng J
    Curr Top Med Chem; 2019; 19(20):1850-1866. PubMed ID: 31448711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARNi: A Novel Approach to Counteract Cardiovascular Diseases.
    Volpe M; Rubattu S; Battistoni A
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
    Floras JS
    Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a future for direct renin inhibitors?
    Chaudhary K; Nistala R; Whaley-Connell A
    Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.